Spanish Healthcare Maintains its Bets on Digitalization

The healthcare business in Spain maintains its strategic bets with a focus on investment and digitalization. Specifically, 86% of companies say that they have launched new initiatives in 2022 aimed at greater digitalization (a ratio that only suffers by four points compared to the previous year), while almost two out of three say they will raise their investments.

These are some of the conclusions of the Barometer of Healthcare Companies in Spain, a report promoted by PlantaDoce, with the sponsorship of Atrys Health, which is based on a survey of close to 300 companies in the healthcare industry in Spain in a broad sense, from the pharmaceutical industry to the clinical sector, medical technology, research and care for dependent persons. The survey was carried out in its entirety in September.

The report reveals that, despite the worst circumstances, affected by the economic environment, the sector’s dynamism in terms of investment, internationalization, and technological innovation has not slowed down. Almost two out of three companies in this business plan to increase their investments in 2022 compared to the previous year: specifically, 26% of the panelists say that their investments will register a substantial increase in 2022 compared to the previous year. This rate falls by nine points from the previous edition when 35% were betting on strongly boosting their investments in the year after the outbreak of the pandemic.

Read more on the subject and find the latest business news of the day with the born2Invest mobile app.

Nearly two out of three companies in expect to increase their investments in 2022 compared to the previous year

On the other hand, the ratio of companies that are betting on a moderate growth of their investments in the current year falls by only one point, to 39% of the total. Only 6% of companies, four points more than in the previous edition of the Barometer, say that their investments will decrease moderately with respect to the previous year. The share that will remain stable is also rising: from 23% in 2021 to 29% this year.

Another strategic focus of many of the sector’s operators is international growth. In 2022, the proportion of companies expecting an increase in international sales fell compared to the previous year: 17% see this as certain (compared to 25% in 2021) and 21% as probable (compared to 22% previously). The majority, 61%, believe that the ratio of international sales will remain stable.

The goal that remains the clearest in the Spanish healthcare sector is that of digitalization

In 2022, 86% of Spanish companies in the sector have launched new initiatives throughout the year aimed at greater digitization, after nine out of ten operators in this industry had already done so in 2021. The challenges in this regard remain, although the note given by the sector itself is positive. Specifically, 2% of Spanish companies in the healthcare business rate the level of development of digital healthcare in Spain as very high, while another 36% rate it as high and another 54% rate it as fair. Only 8% believe, on the other hand, that it is low.

Technology is precisely one of the two trends in the healthcare business that most companies believe will be maintained in the medium and long term. 88% of companies say that digital health and telemedicine will continue to develop in the future, while 70% point to the increased use of data in the sector.

In third place, 41% say that predictive medicine will gain weight, the third trend with the most business support. The report points to other relevant conclusions, such as the increase, from 40% to 42%, in the rate of companies that have carried out or plan to carry out a corporate operation, or the decrease (although still high) in the proportion of companies that expect their business to continue to grow in 2022.

__

(Featured image by geralt via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the articles from the originals. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.